[Clinical investigations of the effect of tolbutamide and glibenclamide on pancreatic glucagon secretion (author's transl)]
- PMID: 811925
- DOI: 10.1007/BF01468901
[Clinical investigations of the effect of tolbutamide and glibenclamide on pancreatic glucagon secretion (author's transl)]
Abstract
The effects of tolbutamide, glibenclamide, arginine and arginine in combination with glibenclamide upon insulin, glucagon and glucose serum levels have been studied in healthy young men. Sulphonylurea-induced hypoglycemia is followed by a reactive hyperglucagonemia. Arginine-induced hyperglucagonemia is not suppressed by sulphonylureas. While there exists no difference between tolbutamide and glibenclamide-stimulated glucagon secretion, there is one with regard to insulin secretion.
Similar articles
-
Modulation of A and B cell functions by tolbutamide and arginine in the pancreas of thiamine-deficient rats.Biochem Int. 1989 Oct;19(4):793-802. Biochem Int. 1989. PMID: 2695088
-
Sulphonylurea (glubenclamide) enhances somatostatin and inhibits glucagon release induced by arginine.Acta Physiol Scand. 1980 Mar;108(3):231-3. doi: 10.1111/j.1748-1716.1980.tb06527.x. Acta Physiol Scand. 1980. PMID: 6103639
-
Suppression of pancreatic glucagon release by the hypoglycaemic sulphonylureas.Lancet. 1969 Jan 25;1(7587):174-6. doi: 10.1016/s0140-6736(69)91189-1. Lancet. 1969. PMID: 4178416 No abstract available.
-
Secretion of glucagon and insulin in hypophysectomized rats: effect of tolbutamide.Horm Res. 1979;11(2):81-91. doi: 10.1159/000179043. Horm Res. 1979. PMID: 383597
-
Diabetes mellitus--a disease of pancreatic and extrapancreatic origin.Adv Metab Disord. 1974;7(0):193-212. doi: 10.1016/b978-0-12-027307-2.50015-3. Adv Metab Disord. 1974. PMID: 4606429 Review. No abstract available.